15 May 2025

Infant receives a base-editing therapy designed for his own mutation

Biotechnology and synthetic biologyMedical technology and bioelectronics
AI illustration · Illustrative scene, not a photograph of the specific device or experiment.

What was demonstrated

After a newborn was diagnosed with severe carbamoyl-phosphate synthetase 1 deficiency, the clinical and research team developed a lipid nanoparticle-delivered base-editing therapy for his specific variant. After regulatory approval, he received two infusions at about 7 and 8 months of age. In the 7 weeks after the first infusion he tolerated more dietary protein and his nitrogen-scavenger dose was halved, with no serious adverse events.

Why it matters

It shows that a bespoke in vivo gene-editing therapy can be designed, manufactured and approved for a single patient within months, a possible model for treating very rare genetic diseases.

Caveats

  • Single patient with short follow-up (7 weeks at the time of the report); long-term safety and efficacy are unknown.
  • Off-target editing and durability of the effect require longer monitoring.
  • The regulatory and manufacturing path used here may not scale easily to many bespoke therapies.

Technology profiles

Sources

  1. peer reviewed paper
    Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease
    Kiran Musunuru, Sarah A. Grandinette, Xiao Wang et al.. New England Journal of Medicine, 15 May 2025. DOI: 10.1056/NEJMoa2504747.

Last reviewed 20 Oct 2026.